WHC is still in active development. Read this to understand our approach.
depiction of AYXYPKUFHZROOJ-UHFFFAOYSA-N.svg
tripsit

pregabalin

Verificar en tripsit

psychonaut

Pregabalin

Verificar en psychonaut

isomerdesign

Pregabalin

Verificar en isomerdesign

pubchem

Pregabalin

Verificar en pubchem

druglab

Prégabaline

Verificar en druglab

drugmap

Pregabalin

Verificar en drugmap

drugmap

Pregabalin

Verificar en drugmap

drugmap

Pregabalin

Verificar en drugmap

wiki

Pregabalin

Verificar en wiki

Data

InChI: InChI=1S/C8H17NO2/c1-6(2)3-7(5-9)4-8(10)11/h6-7H,3-5,9H2,1-2H3,(H,10,11)

Sinónimos: SR-01000942257-2,SCHEMBL8227,Pregabalin mylan, CCG-40213,CI 1008,KS-5378,148553-51-9,PREGABALIN [MI],Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)-,(S)-3-(Aminomethyl)-5-methylhexanoic acid, CA-452, AC1NFWUF,PREGABALIN [USP MONOGRAPH],Pregabalin 1.0 mg/ml in Methanol,pregablin,HSDB 7530,BDBM50164279,121GE001,(3S)-3-(aminomethyl)-5-methylhexanoic acid,CAS-148553-50-8,Lyrica;CI-1008;PD-144723,PD144723, CHEMBL88034,PREGABALIN [JAN],NSC 759256,Q412174,Nervalin, PubChem15652,(3S)-3-(Aminomethyl)-5-methylhexanoic acid,Pregabaline,Pregabalin,CI-1008,(S)-3-(Aminomethyl)-5-methylhexanoicacid,HY-17414,DEA No. 2782, HMS2093F10,(3S)-3-(aminomethyl)-5-methyl hexanoic acid,A808784, TOS-0910,553P508,DTXSID1045950,AKOS005145504, SC-94803,NSC-759256, PD 144550,148553-50-8,Pregabalin, EuropePharmacopoeia (EP) Reference Standard, Pregabalin (controlled-release, oral),SR-01000942257, (3R)-3-(aminomethyl)-5-methylhexanoic acid,PREGABALIN [MART.],(S)-(+)-3-Aminomethyl-5-Methylhexanoic Acid, (R)-3-(Aminomethyl)-5-methylhexanoic acid,Pregablin,CS-1247,DSSTox_RID_81246,D02716, BCP17115,Lyrica (TN), ZINC5760031,(S)-3-aminomethyl-5-methylhexanoic acid,Pregabalina, AC1L2PDQ,DSSTox_CID_25950,NCGC00095186-01,AKOS001476611, 3-(Aminomethyl)-5-methylhexanoicacid, NSC759256, DTXSID90276292, BSPBio_002316,1414928-41-8, NCGC00095186-01, Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3R)-,Pregabalin (JAN/USAN/INN), SCHEMBL263450,(3S)-3-(aminomethyl)-5-methyl-hexanoic acid,3-Aminomethyl-5-methyl-hexanoic acid,Pregabalin zentiva, NSC-759256,GTPL5484, BBL100350,PREGABALIN [ORANGE BOOK], (R)-Pregabalin,3-Isobutyl GABA, rac-Pregabalin,DTXCID9025950,Pregabalin CR,LYRICA CR, Pharmakon1600-01505816,Pregabalin sandoz, 130912-52-6,CCG-221247,Pregabalin- Bio-X,AB01563007_01,PD-144550,(R-)-3-isobutyl GABA, KS-00000AKV, Pregabalin (controlled-release, oral), Pfizer, Hexanoic acid, 3-(aminomethyl)-5-methyl-, CHEMBL167003,PREGABALIN [USP-RS], 128013-69-4,ZINC5152, NCGC00178709-01,PREGABALIN [WHO-DD], SBI-0206875.P001,CHEMBL1059, K-4720,Vronogabic,BP163672,PREGABALIN [EP MONOGRAPH], 3-(aminomethyl)-5-methyl-hexanoic acid,P2840,PD 144723, ACMC-20p1cu,(S)-Pregabalin,Pregabalin [USAN],PREGABALIN [VANDF],NCGC00346738-01, ANW-51583, PD-144550,Pregabalin, >=97% (NMR),MFCD00917044,Hexanoic acid, 3-(aminomethyl)-5-ethyl-, (3S)-, ent-Pregabalin, SPECTRUM1505816,Pregabalin [USAN:INN:BAN:JAN], Hexanoic acid,3-(aminomethyl)-5-methyl-,PD-144723, PHARMA-0589,UNII-55JG375S6M,EN300-92104,55JG375S6M, ACMC-1CF05,(S)-3-Aminomethyl-5-methyl-hexanoic acid,CHEBI:64356,(S)-(+)-4-amino-3-(2-methylpropyl)butanoic acid,PREGABALIN [HSDB],Pregabalin sandoz gmbh, FT-0600823, AKOS027425242, STK894330,Hexanoic acid, 3-(aminomethyl)-5-methyl-, (S)-,(S)-3-Isobutyl GABA, R-Pregabalin, BCP05685, FT-0674010,AC-1158,YNP-1807,Z2757554242,3-(aminomethyl)-5-methylhexanoic acid,PREGABALIN [INN], CTK4B5836,lyrica,Tox21_111475, FC0023,3-isobutyl GABA,DB00230,PREGABALIN MYLAN PHARMA,AM20080369, HMS1922H16,DSSTox_GSID_45950, SCHEMBL15497,HMS3715J16,PREGABALIN [EMA EPAR],Lyrica, AYXYPKUFHZROOJ-UHFFFAOYSA-N

Estimated data

Solubilidad: -0.641 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 61.5% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.